METHODS
• Primary research was conducted to assess how value added medicines might respond to various stakeholders' and society needs.  Twenty European stakeholders among healthcare professionals, regulatory authorities and HTA bodies/payers (Country scope: Austria, Belgium, France, Germany, Italy, Poland, Spain, The Netherlands, Scotland, Sweden) were interviewed using a standardised discussion guide.  A written survey complemented by a focus group were conducted among representatives of pharmaceutical industry developing medicines in this field.
• Ad hoc literature review was conducted to illustrate, when appropriate, statements of the various stakeholders, especially targeting healthcare inefficiencies related to medicines. CONCLUSIONS
• Value added medicines represent an opportunity for society to address a number of medicine related healthcare inefficiencies and also present an opportunity to deliver better health to patients, to enhance healthcare system efficiency and contribute to the sustainability of the healthcare systems. • Stakeholders' interviews highlighted three main potential benefits for value added medicines:
1. To address some healthcare system inefficiencies related to medicines. (Figure 2 ) 2. To improve healthcare system efficiency through the opportunity to better address healthcare provision and organisation.
 Value added medicines could contribute to reduction and re-allocation in healthcare use (e.g. a ready to use chemotherapy which might improve medicine handling and save time for healthcare providers).
3. To contribute to sustainability of healthcare systems through economic advantages. New drug formulations or drug combinations
• Could contribute to limit off-label use of medicines Drug repositioning but also drug reformulations for specific patient groups
• Could contribute to limit medicine wastage New and appropriate drug packaging and vial conditioning
Value added medicines could contribute to address the nonavailability of appropriate treatment options
• Represent an opportunity to tailor and expand access of wellknown therapies to particular patient subgroups' needs
• Could contribute to the faster development of new therapeutic options in areas of unmet medical needs benefiting from the knowledge gained from the previous medicine development; it may also happen through the evolution of scientific knowledge
Value added medicines could contribute to address the shortage of mature products
• Provide opportunity to create new market attractiveness of mature products which may avoid product shortage in some countries
Value added medicines might contribute to address geographical inequities
• By the opportunity they represent to create an intermediate step before switching to costly products, thus improving the affordability • By the opportunity they represent to provide new medicine formulations for hospital-only medicines which could be used in out-patient settings, thus improving access in remote rural areas for example 
